| [ Summary ] |
A constellation of metabolic abnormalities, which includes dyslipidemia, dysglycemia, obesity of the visceral type and hypertension is referred to as “metabolic syndrome”. The affects of this syndrome substantially increase the risk of cardiovascular disease (CVD) as well as the development and progression of renal dysfunction, along with aortic aneurysms and obstructive arteriosclerosis. Obesity, especially the visceral type, is associated with secretion of several adipocytokines from adipose tissue, which induce peripheral resistance to insulin actions and hyperinsulinemia, which leads to a predisposition to the developmemt of diabetes. Recently, microalbuminuria has been begun to be accepted as a component and marker for metabolic syndrome, in addition to being an early marker for progressive renal disease, cardiovascular disease, and increased mortality rates in patients with this syndrome. This review examines the role of metabolic syndrome in patients with chronic renal disease, the progression of renal disease, accelerated CVD, as well as the importance of microalbuminuria as an early marker for metabolic syndrome. It also describes the management of these conditions based on clinical evidence. |